NUCLIDIUM receives Innosuisse grant to establish new PET tracers based on its proprietary Copper-61 Platform
Innosuisse has awarded Nuclidium with a €1 million grant to further advance its development of a proprietary platform of novel PET tracers based on Copper-61.
Nuclidium has won a second Innosuisse Grant of €800.000 to improve treatment of carcinomas via precision imaging of the tumour microenvironment with a novel Copper-61-based PET tracer.
The European Innovation Council (EIC) has awarded Nuclidium with its Accelerator grant of €2,5 million to develop novel, broadly available Copper-based PET tracers for the diagnosis of a broad range of cancer indications.